New 5,000-plex gene panel increases plex
by an order of magnitude and delivers industry-leading speed and
throughput
PLEASANTON, Calif., June 20,
2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, announced today
that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel
features an enhanced chemistry to increase plex by an order of
magnitude while delivering excellent per-gene sensitivity, improved
specificity and spatial fidelity, integrated multimodal cell
segmentation and industry-leading speed and throughput.
"It's been awesome to see the early enthusiasm for the
5K gene panel from our customers, who
appreciate the product for both its high plex and its high
performance," said Ben
Hindson, Co-Founder and Chief Scientific Officer at 10x
Genomics. "Xenium Prime 5K is an
incredible product that delivers outstanding results across every
metric that matters, including sensitivity, specificity and
throughput. This is our fifth major product launch this year, as we
continue to deliver ground-breaking innovations to help customers
pursue ground-breaking discoveries."
Key features of the new high-plex Xenium Prime 5K assay include:
- Highest plex Xenium panel containing 5,000 genes for the
comprehensive profiling of cell types and states and cell signaling
pathways across multiple tissue and disease types.
- Excellent data quality to unlock mechanisms of disease,
therapeutics and cell behavior. The Xenium Prime 5K assay is optimized for performance and paired
with 10x Genomics' advanced multimodal cell segmentation, enabling
high sensitivity, specificity and spatial fidelity.
- Rapid turnaround time. 10x Genomics' industry-leading
throughput enables researchers to analyze up to 472 mm² of human or
mouse tissue in six days or less.
- Easily customizable with up to 100 additional genes,
including isoforms, exogenous sequences like gRNAs and barcodes,
CAR-T transcripts, viruses and more.
- Rigorously designed and developed using single cell
RNA-seq data from dozens of different organs and tissues, gene
expression profiles from hundreds of cell types and a screen of
more than 750,000 peer-reviewed publications to pinpoint highly
cited biomarkers.
- Easy, tissue-agnostic workflow compatible with both
fresh frozen and FFPE samples.
The company will host a webinar to introduce the Xenium Prime
5K Pan-Tissue and Pathways panel on
June 25, 2024 at 9 a.m. Pacific Time. Interested attendees can
register here.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration and capabilities. These statements are based on
management's current expectations, forecasts, beliefs, assumptions
and information currently available to management, and actual
outcomes and results could differ materially from these statements
due to a number of factors. Other risks and uncertainties that
could affect 10x Genomics' financial and operating results and
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release include
those discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents 10x Genomics files with
the Securities and Exchange Commission (the "SEC") from time to
time. Although 10x Genomics believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to 10x Genomics as of the date hereof, and
10x Genomics disclaims any obligation to update any forward-looking
statements provided to reflect any change in its expectations or
any change in events, conditions or circumstances on which any such
statement is based, except as required by law. These
forward-looking statements should not be relied upon as
representing 10x Genomics' views as of any date subsequent to the
date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-begins-commercial-shipments-of-xenium-prime-5k-pan-tissue-and-pathways-panel-302177116.html
SOURCE 10x Genomics, Inc.